What Caused CERo Therapeutics Stock to Plummet 80% Today?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 30 2025
0mins
Source: TipRanks
Delisting Notice: CERo Therapeutics (CERO) stock fell sharply after receiving a delisting notice from Nasdaq for failing to maintain the required stockholders’ equity of at least $2.5 million.
Stock Performance: The stock dropped 81.28% in pre-market trading, extending a year-to-date decline of 98.51% and a 90.96% drop over the past 12 months.
Future Plans: The company plans to appeal the delisting decision and is preparing to switch to an OTC market listing, though success is uncertain and could negatively impact stock prices.
Analyst Ratings: Despite the delisting news, analysts had previously rated CERO as a Moderate Buy, but this rating is expected to change following the recent developments.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
